GeoVax Labs (GOVX) Scheduled to Post Earnings on Tuesday

GeoVax Labs (NASDAQ:GOVX) is scheduled to release its earnings data after the market closes on Tuesday, November 12th. Analysts expect GeoVax Labs to post earnings of ($1.29) per share for the quarter.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.57) by $0.58. The company had revenue of $0.30 million during the quarter. During the same quarter in the prior year, the company posted ($3.30) earnings per share. On average, analysts expect GeoVax Labs to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $1.81 on Wednesday. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18. The company has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $2.56.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Monday, August 12th. Noble Financial lifted their price objective on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, August 19th. Roth Mkm initiated coverage on GeoVax Labs in a research report on Tuesday, July 16th. They set a “buy” rating and a $20.00 target price on the stock. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Finally, Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, GeoVax Labs currently has an average rating of “Buy” and a consensus price target of $12.67.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.